Pseudophakic cystoid macular edema (PCME), or Irvine-Gass syndrome, is retinal thickening of
the macula, which usually develops within 3 months after surgery, with a peak incidence
between 4 and 6 weeks. Despite recent improvements in surgical techniques, PCME remains one
of the most common causes of visual decline following an uneventful cataract surgery.
Symptoms of PCME usually are blurred vision, metamorphopsia, loss of contrast sensitivity,
and central scotomas. PCME usually responds well to medical therapy or may resolve
spontaneously but carries a risk of permanent vision loss or loss of contrast sensitivity.
There is wide discrepancy in opinions about the most effective antiinflammatory drops for the
prevention of PCME. Patients with diabetes mellitus (DM) have attracted special interest
because of higher incidence of cataract and increased risk for developing CME after cataract
surgery. The optimum antiinflammatory prophylaxis for PCME in patients with nonproliferative
diabetic retinopathy (NPDR) remains unknown.
Purpose of this study is to determine the efficacy of topical bromfenac and topical
dexamethasone on intraocular concentration of interleukin-6 (IL6) and the incidence of
pseudophakic cystoid macular edema (PCME) after cataract surgery in patients with
nonproliferative diabetic retinopathy (NPDR).